Cresaryn is developing its tadalafil oro-buccal spray through a proposed United States 505(b)(2) pathway. This route may permit an application to rely partly on FDA findings or published information relating to an already approved active ingredient, while providing new evidence needed for the NanoCelle formulation, route, device and proposed product claims. The final regulatory strategy, reference product, required studies and submission content remain subject to FDA agreement.
The lead formulation has been selected. Work includes bio-analytical method validation, stability, product specifications, manufacturing controls, device configuration, batch supply and preparation of a scalable CMC package.
Because the product uses an oro-buccal route and includes excipients requiring justification, local tolerance is a key development gate. A 30-day minipig study with recovery is intended to evaluate oral and buccal safety. Preliminary data may support ethics review if results are acceptable; the full study package will support later regulatory activities.
The first planned human study is a small, single-dose comparison intended to characterise pharmacokinetics, safety and tolerability across Cresaryn doses and an oral tadalafil comparator. Human onset and efficacy claims are not established. Protocol finalisation, investigator documentation, product supply, ethics approval and adequate local-safety justification are prerequisites.
Regulatory interaction will confirm the 505(b)(2) logic, nonclinical expectations, clinical program, reference products, CMC and device requirements. The preferred transaction window begins around IND opening, when the US development pathway should be clearer.
Planning assumptions include agreed bioequivalence or pivotal clinical work, additional safety or chronic toxicology where required, CMC validation, stability, device qualification and human-factors activities. The exact package cannot be finalised before FDA advice.
Current integrated planning uses a December 2028 NDA submission estimate, followed by FDA review. This is an illustrative project-planning date, not regulatory guidance or a guaranteed approval timeline.